{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:43:46Z","timestamp":1787021026449,"version":"build-2736575974"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T00:00:00Z","timestamp":1737158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T00:00:00Z","timestamp":1737158400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"FONDECYT Postdoctorado","award":["3210629"],"award-info":[{"award-number":["3210629"]}]},{"name":"FONDECYT Postdoctorado","award":["3210687"],"award-info":[{"award-number":["3210687"]}]},{"name":"FONDECYT Regular","award":["1210440"],"award-info":[{"award-number":["1210440"]}]},{"name":"FONDECYT Regular","award":["1211223"],"award-info":[{"award-number":["1211223"]}]},{"DOI":"10.13039\/501100018735","name":"FONDAP","doi-asserted-by":"crossref","award":["15130011"],"award-info":[{"award-number":["15130011"]}],"id":[{"id":"10.13039\/501100018735","id-type":"DOI","asserted-by":"crossref"}]},{"name":"FONDEF VIU","award":["20P0023"],"award-info":[{"award-number":["20P0023"]}]},{"name":"FONDEF IDEA","award":["ID21I10027"],"award-info":[{"award-number":["ID21I10027"]}]},{"name":"FONDEF Idea","award":["ID21I10027"],"award-info":[{"award-number":["ID21I10027"]}]},{"DOI":"10.13039\/501100013928","name":"Instituto Milenio en Inmunolog\u00eda e Inmunoterapia","doi-asserted-by":"publisher","award":["ICN2021_045"],"award-info":[{"award-number":["ICN2021_045"]}],"id":[{"id":"10.13039\/501100013928","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013928","name":"Instituto Milenio en Inmunolog\u00eda e Inmunoterapia","doi-asserted-by":"publisher","award":["ICN09_016"],"award-info":[{"award-number":["ICN09_016"]}],"id":[{"id":"10.13039\/501100013928","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013928","name":"Instituto Milenio en Inmunolog\u00eda e Inmunoterapia","doi-asserted-by":"publisher","award":["formerP09\/016-F"],"award-info":[{"award-number":["formerP09\/016-F"]}],"id":[{"id":"10.13039\/501100013928","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014171","name":"Biomedical Research Consortium-Chile","doi-asserted-by":"publisher","award":["Biomedical Research Consortium-Chile"],"award-info":[{"award-number":["Biomedical Research Consortium-Chile"]}],"id":[{"id":"10.13039\/501100014171","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Advanced Research Grant from Universidad Aut\u00f3noma de Chile","award":["DIUAV 03-2022"],"award-info":[{"award-number":["DIUAV 03-2022"]}]},{"name":"Advanced Research Grant from Universidad Aut\u00f3noma de Chile","award":["DIUAV 03-2022"],"award-info":[{"award-number":["DIUAV 03-2022"]}]},{"name":"ANID-MILENIO","award":["NCS2021-013"],"award-info":[{"award-number":["NCS2021-013"]}]},{"name":"Research Grant from Universidad Aut\u00f3noma de Chile","award":["DIUA 307-2024"],"award-info":[{"award-number":["DIUA 307-2024"]}]},{"name":"Interuniversity project","award":["IUP23-20"],"award-info":[{"award-number":["IUP23-20"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Biol Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Gastric cancer (GC) is a significant cancer-related cause of death worldwide. GC\u2019s most used chemotherapeutic regimen is based on platinum drugs such as cisplatin (CDDP). However, CDDP chemoresistance reduces the survival rate of advanced GC. The immune C-C chemokine receptor type 5 (CCR5) have been proposed as a pivotal factor in cancer progression since its blockade has been linked with antineoplastic effects on tumor cell proliferation; nevertheless, its role in the chemoresistance of GC has not been elucidated. This study aimed to determine the effects induced by the CCR5 using Maraviroc (MVC), a highly selective CCR5 antagonist, on CDDP-resistant AGS cells (AGS R-CDDP), tumoroids (\n                      <jats:italic>3D<\/jats:italic>\n                      tumor spheroids), and animal models.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The combined CDDP and MVC treatment reduced cell viability and inhibited tumoroid formation in AGS R-CDDP cells. The effects of the MVC\/CDDP combination on apoptosis and cell cycle progression were correlated with the increase in CDDP (dose-dependent). The mRNA levels of C-C Motif Chemokine Ligand 5 (CCL5), the main ligand for CCR5, decreased significantly in cells treated with the MVC\/CDDP combination. MVC in the MVC\/CDDP combination improved the survival rate and biochemical parameters of CDDP-treated mice by reducing the side effects of CDDP alone.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This finding suggests that MVC\/CDDP combination could be a potential complementary therapy for GC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40659-024-00581-3","type":"journal-article","created":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T00:01:04Z","timestamp":1737158464000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Maraviroc\/cisplatin combination inhibits gastric cancer tumoroid growth and improves mice survival"],"prefix":"10.1186","volume":"58","author":[{"given":"B\u00e1rbara","family":"Mora-Lagos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Elena","family":"Reyes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorena","family":"Lobos-Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mat\u00edas","family":"del Campo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurt","family":"Buchegger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Zanella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ismael","family":"Riquelme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen Gloria","family":"Ili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3896-146X","authenticated-orcid":false,"given":"Priscilla","family":"Brebi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,18]]},"reference":[{"issue":"3","key":"581_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"581_CR2","doi-asserted-by":"publisher","first-page":"318","DOI":"10.2174\/1871520615666150803125121","volume":"16","author":"JJG Marin","year":"2016","unstructured":"Marin JJG, Al-Abdulla R, Lozano E, Briz O, Bujanda L, Banales M. Mechanisms of resistance to Chemotherapy in Gastric Cancer. Anticancer Agents Med Chem. 2016;16(3):318\u201334.","journal-title":"Anticancer Agents Med Chem"},{"key":"581_CR3","doi-asserted-by":"publisher","first-page":"527","DOI":"10.2217\/fon.10.21","volume":"6","author":"D Zhang","year":"2010","unstructured":"Zhang D, Fan D. New insights into the mechanisms of gastric cancer multidrug resistance and future perspectives. Future Oncol. 2010;6:527\u201337.","journal-title":"Future Oncol"},{"key":"581_CR4","doi-asserted-by":"crossref","unstructured":"DIgklia A, Wagner AD. Advanced gastric cancer: current treatment landscape and future perspectives. World J Gastroenterol. 2016.","DOI":"10.3748\/wjg.v22.i8.2403"},{"issue":"8215","key":"581_CR5","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/S0140-6736(81)91928-0","volume":"1","author":"RJ Keehn","year":"1981","unstructured":"Keehn RJ, Higgins GA. Chemotherapy for gastric cancer. Lancet. 1981;1(8215):323.","journal-title":"Lancet"},{"issue":"4","key":"581_CR6","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/nrd1691","volume":"4","author":"D Wang","year":"2005","unstructured":"Wang D, Lippard SJ. Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov. 2005;4(4):307\u201320.","journal-title":"Nat Rev Drug Discov"},{"issue":"9","key":"581_CR7","doi-asserted-by":"publisher","first-page":"673","DOI":"10.4251\/wjgo.v8.i9.673","volume":"8","author":"WJ Shi","year":"2016","unstructured":"Shi WJ, Gao JB. Molecular mechanisms of chemoresistance in gastric cancer. World J Gastrointest Oncol. 2016;8(9):673.","journal-title":"World J Gastrointest Oncol"},{"issue":"3","key":"581_CR8","doi-asserted-by":"publisher","first-page":"3527","DOI":"10.1007\/s13277-015-4144-1","volume":"37","author":"H Huang","year":"2016","unstructured":"Huang H, Han Y, Zhang C, Wu J, Feng J, Qu L, et al. HNRNPC as a candidate biomarker for chemoresistance in gastric cancer. Tumour Biol. 2016;37(3):3527\u201334.","journal-title":"Tumour Biol"},{"key":"581_CR9","doi-asserted-by":"crossref","unstructured":"Chen SH, Chang JY. New insights into mechanisms of cisplatin resistance: from tumor cell to microenvironment. Int J Mol Sci. 2019;20(17).","DOI":"10.3390\/ijms20174136"},{"issue":"12","key":"581_CR10","doi-asserted-by":"publisher","first-page":"777","DOI":"10.2217\/pgs-2021-0020","volume":"22","author":"Y Mora","year":"2021","unstructured":"Mora Y, Reyes ME, Zanella L, Mora B, Buchegger K, Ili C, et al. Resistance to platinum-based cancer drugs: a special focus on epigenetic mechanisms. Pharmacogenomics. 2021;22(12):777\u201390.","journal-title":"Pharmacogenomics"},{"key":"581_CR11","doi-asserted-by":"crossref","unstructured":"Reyes ME, de La Fuente M, Hermoso M, Ili CG, Brebi P. Role of CC chemokines Subfamily in the platinum drugs Resistance Promotion in Cancer. Front Immunol. 2020.","DOI":"10.3389\/fimmu.2020.00901"},{"key":"581_CR12","doi-asserted-by":"crossref","unstructured":"Mora-Lagos B, Cartas-Espinel I, Riquelme I, Parker AC, Piccolo SR, Viscarra T et al. Functional and transcriptomic characterization of cisplatin-resistant AGS and MKN-28 gastric cancer cell lines. PLoS ONE. 2020.","DOI":"10.1371\/journal.pone.0228331"},{"key":"581_CR13","doi-asserted-by":"crossref","unstructured":"Aldinucci D, Borghese C, Casagrande N. The CCL5\/CCR5 Axis in Cancer Progression. Cancers (Basel). 2020;12(7).","DOI":"10.3390\/cancers12071765"},{"key":"581_CR14","doi-asserted-by":"crossref","unstructured":"Ryu H, Baek S, Moon J, Jo I, Kim N, Lee H. CC motif chemokine receptors in gastric cancer (review). Mol Clin Oncol. 2017.","DOI":"10.3892\/mco.2017.1470"},{"key":"581_CR15","doi-asserted-by":"crossref","unstructured":"Jiao X, Nawab O, Patel T, Kossenkov AV, Halama N, Jaeger D et al. Recent advances targeting CCR5 for cancer and its role in immuno-oncology. Cancer Res. 2019.","DOI":"10.1158\/0008-5472.CAN-19-1167"},{"key":"581_CR16","doi-asserted-by":"crossref","unstructured":"Aldinucci D, Casagrande N. Inhibition of the CCL5\/CCR5 Axis against the Progression of Gastric Cancer. Int J Mol Sci [Internet]. 2018;19(5):1477. https:\/\/pubmed.ncbi.nlm.nih.gov\/29772686","DOI":"10.3390\/ijms19051477"},{"issue":"8","key":"581_CR17","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.3390\/ijms18081824","volume":"18","author":"N Mukaida","year":"2017","unstructured":"Mukaida N, Tanabe Y, Baba T. Chemokines as a conductor of bone marrow microenvironment in chronic myeloid leukemia. Int J Mol Sci. 2017;18(8):1824.","journal-title":"Int J Mol Sci"},{"key":"581_CR18","doi-asserted-by":"crossref","unstructured":"Velasco-velazquez M, Jiao X, Fuente MD, La, Pestell TG. CCR5 antagonist blocks metastasis of basal breast Cancer cells CCR5 antagonist blocks metastasis of basal breast Cancer cells. 2012;(December 2015).","DOI":"10.1158\/0008-5472.CAN-11-3917"},{"issue":"12","key":"581_CR19","doi-asserted-by":"publisher","first-page":"e28842","DOI":"10.1371\/journal.pone.0028842","volume":"6","author":"B Cambien","year":"2011","unstructured":"Cambien B, Richard-Fiardo P, Karimdjee BF, Martini V, Ferrua B, Pitard B, et al. CCL5 neutralization restricts Cancer Growth and Potentiates the Targeting of PDGFR\u03b2 in Colorectal Carcinoma. PLoS ONE. 2011;6(12):e28842.","journal-title":"PLoS ONE"},{"issue":"10","key":"581_CR20","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1080\/15384047.2017.1373219","volume":"18","author":"T Yang","year":"2017","unstructured":"Yang T, Chen M, Yang X, Zhang X, Zhang Z, Sun Y, et al. Down-regulation of KLF5 in cancer-associated fibroblasts inhibit gastric cancer cells progression by CCL5\/CCR5 axis. Cancer Biol Ther. 2017;18(10):806\u201315.","journal-title":"Cancer Biol Ther"},{"issue":"1","key":"581_CR21","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s13402-018-0415-3","volume":"42","author":"A Pervaiz","year":"2019","unstructured":"Pervaiz A, Zepp M, Mahmood S, Ali DM, Berger MR, Adwan H. CCR5 blockage by maraviroc: a potential therapeutic option for metastatic breast cancer. Cell Oncol. 2019;42(1):93\u2013106.","journal-title":"Cell Oncol"},{"key":"581_CR22","doi-asserted-by":"crossref","unstructured":"Ding H, Zhao L, Dai S, Li L, Wang F, Shan B. CCL5 secreted by tumor associated macrophages may be a new target in treatment of gastric cancer. Biomed Pharmacotherapy. 2016.","DOI":"10.1016\/j.biopha.2015.12.004"},{"key":"581_CR23","doi-asserted-by":"crossref","unstructured":"Mencarelli A, Graziosi L, Renga B, Cipriani S, D\u2019Amore C, Francisci D et al. CCR5 antagonism by maraviroc reduces the potential for gastric cancer cell dissemination. Transl Oncol. 2013.","DOI":"10.1593\/tlo.13499"},{"issue":"1","key":"581_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40659-023-00477-8","volume":"57","author":"E Dur\u00e1n-Jara","year":"2024","unstructured":"Dur\u00e1n-Jara E, del Campo M, Guti\u00e9rrez V, Wichmann I, Trigo C, Ezquer M, et al. Lactadherin immunoblockade in small extracellular vesicles inhibits sEV-mediated increase of pro-metastatic capacities. Biol Res. 2024;57(1):1.","journal-title":"Biol Res"},{"key":"581_CR25","doi-asserted-by":"publisher","unstructured":"Lobos-Gonz\u00e1lez L, Aguilar L, Diaz J, Diaz N, Urra H, Torres VA et al. E-cadherin determines Caveolin-1 tumor suppression or metastasis enhancing function in melanoma cells. Pigment Cell Melanoma Res [Internet]. 2013;26(4):555\u201370. https:\/\/onlinelibrary.wiley.com\/doi\/abs\/https:\/\/doi.org\/10.1111\/pcmr.12085","DOI":"10.1111\/pcmr.12085"},{"key":"581_CR26","doi-asserted-by":"crossref","unstructured":"Lobos-Gonzalez L, Aguilar-Guzm\u00e1n L, Fernandez JG, Mu\u00f1oz N, Hossain M, Bieneck S et al. Caveolin-1 is a risk factor for postsurgery metastasis in preclinical melanoma models. Melanoma Res [Internet]. 2014;24(2). https:\/\/journals.lww.com\/melanomaresearch\/fulltext\/2014\/04000\/caveolin_1_is_a_risk_factor_for_postsurgery.3.aspx","DOI":"10.1097\/CMR.0000000000000046"},{"key":"581_CR27","doi-asserted-by":"crossref","unstructured":"Xu H, Bin, Shen FM, Lv QZ. Celecoxib enhanced the cytotoxic effect of cisplatin in chemo-resistant gastric cancer xenograft mouse models through a cyclooxygenase-2-dependent manner. Eur J Pharmacol. 2016.","DOI":"10.1016\/j.ejphar.2016.02.035"},{"issue":"1","key":"581_CR28","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1038\/s41598-018-19643-0","volume":"8","author":"SK Singh","year":"2018","unstructured":"Singh SK, Mishra MK, Eltoum IEA, Bae S, Lillard JW, Singh R. CCR5\/CCL5 axis interaction promotes migratory and invasiveness of pancreatic cancer cells. Sci Rep. 2018;8(1):1323.","journal-title":"Sci Rep"},{"issue":"4","key":"581_CR29","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.ccell.2016.03.005","volume":"29","author":"N Halama","year":"2016","unstructured":"Halama N, Zoernig I, Berthel A, Grabe N, Falk CS, Jaeger D, et al. Tumoral Immune Cell Exploitation in Colorectal Cancer metastases can be targeted effectively by Anti-CCR5 therapy in Cancer patients Article Tumoral Immune Cell Exploitation in Colorectal Cancer metastases can be targeted effectively by Anti-CCR5 therapy. Cancer Cell. 2016;29(4):587\u2013601.","journal-title":"Cancer Cell"},{"issue":"2","key":"581_CR30","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.bbcan.2016.03.005","volume":"1865","author":"VS Jones","year":"2016","unstructured":"Jones VS, Huang RY, Chen LP, Chen ZS, Fu L, Huang RP. Cytokines in cancer drug resistance: cues to new therapeutic strategies. Biochim Biophys Acta Rev Cancer. 2016;1865(2):255\u201365.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"581_CR31","doi-asserted-by":"crossref","unstructured":"Pasquier J, Gosset M, Geyl C, Hoarau-V\u00e9chot J, Chevrot A, Pocard M et al. CCL2\/CCL5 secreted by the stroma induce IL-6\/PYK2 dependent chemoresistance in ovarian cancer. Mol Cancer. 2018.","DOI":"10.1186\/s12943-018-0787-z"},{"issue":"5","key":"581_CR32","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.3892\/ijo.2016.3442","volume":"48","author":"B Zhou","year":"2016","unstructured":"Zhou B, Sun C, Li N, Shan W, Lu H, Guo L, et al. Cisplatin-induced CCL5 secretion from CAFs promotes cisplatin-resistance in ovarian cancer via regulation of the STAT3 and PI3K\/Akt signaling pathways. Int J Oncol. 2016;48(5):2087\u201397.","journal-title":"Int J Oncol"},{"key":"581_CR33","doi-asserted-by":"crossref","unstructured":"Jones VS, Huang RY, Chen LP, Chen ZS, Fu L, Huang RP. Cytokines in cancer drug resistance: cues to new therapeutic strategies. Biochimica et Biophysica Acta - Reviews on Cancer; 2016.","DOI":"10.1016\/j.bbcan.2016.03.005"},{"key":"581_CR34","doi-asserted-by":"crossref","unstructured":"Casagrande N, Borghese C, Visser L, Mongiat M, Colombatti A, Aldinucci D. CCR5 antagonism by maraviroc inhibits hodgkin lymphoma microenvironment interactions and xenograft growth. Haematologica. 2019.","DOI":"10.3324\/haematol.2018.196725"},{"key":"581_CR35","doi-asserted-by":"crossref","unstructured":"Rocha CRR, Silva MM, Quinet A, Cabral-neto JB, Menck FMC. DNA repair pathways and cisplatin resistance: an intimate relationship. Clinics. 2018.","DOI":"10.6061\/clinics\/2018\/e478s"},{"issue":"6","key":"581_CR36","doi-asserted-by":"publisher","first-page":"4605","DOI":"10.3892\/ol.2016.5288","volume":"12","author":"P Wang","year":"2016","unstructured":"Wang P, Cui J, Wen J, Guo Y, Zhang L, Chen X. Cisplatin induces HepG2 cell cycle arrest through targeting specific long noncoding RNAs and the p53 signaling pathway. Oncol Lett. 2016;12(6):4605\u201312.","journal-title":"Oncol Lett"},{"issue":"3","key":"581_CR37","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1001\/archotol.132.3.317","volume":"132","author":"HT Yip","year":"2006","unstructured":"Yip HT, Chopra R, Chakrabarti R, Veena MS, Ramamurthy B, Srivatsan ES, et al. Cisplatin-Induced growth arrest of Head and Neck Cancer cells correlates with increased expression of p16 and p53. Arch Otolaryngol Head Neck Surg. 2006;132(3):317.","journal-title":"Arch Otolaryngol Head Neck Surg"},{"issue":"2","key":"581_CR38","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1124\/jpet.105.084053","volume":"314","author":"ZY Xu","year":"2005","unstructured":"Xu ZY, Loignon M, Han FY, Panasci L, Aloyz R. Xrcc3 induces cisplatin resistance by stimulation of Rad51-related recombinational repair, S-phase checkpoint activation, and reduced apoptosis. J Pharmacol Exp Ther. 2005;314(2):495\u2013505.","journal-title":"J Pharmacol Exp Ther"},{"key":"581_CR39","doi-asserted-by":"crossref","unstructured":"Li Lya, Guan Y di, Chen X, sha, Yang J ming, Cheng Y. DNA Repair Pathways in Cancer Therapy and Resistance. Front Pharmacol. 2021;11.","DOI":"10.3389\/fphar.2020.629266"},{"key":"581_CR40","doi-asserted-by":"crossref","unstructured":"Jiao X, Velasco-Velazquez MA, Wang M, Li Z, Rui H, Peck AR et al. CCR5 governs DNA damage repair and breast cancer stem cell expansion. Cancer Res. 2018.","DOI":"10.1158\/0008-5472.CAN-17-0915"},{"issue":"10","key":"581_CR41","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1038\/nrc3599","volume":"13","author":"C Holohan","year":"2013","unstructured":"Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer. 2013;13(10):714\u201326.","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"581_CR42","doi-asserted-by":"publisher","first-page":"339","DOI":"10.15171\/apb.2017.041","volume":"7","author":"B Mansoori","year":"2017","unstructured":"Mansoori B, Mohammadi A, Davudian S, Shirjang S, Baradaran B. The different mechanisms of Cancer Drug Resistance: a brief review. Adv Pharm Bull. 2017;7(3):339\u201348.","journal-title":"Adv Pharm Bull"},{"key":"581_CR43","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.3390\/cancers6031769","volume":"6","author":"G Housman","year":"2014","unstructured":"Housman G, Byler S, Heerboth S, Lapinska K, Longacre M, Snyder N, et al. Drug resistance in cancer: an overview. Cancers. 2014;6:1769\u201392.","journal-title":"Cancers"},{"key":"581_CR44","doi-asserted-by":"publisher","unstructured":"Sandoval-B\u00f3rquez A, Polakovicova I, Carrasco-V\u00e9liz N, Lobos-Gonz\u00e1lez L, Riquelme I, Carrasco-Avino G et al. MicroRNA-335-5p is a potential suppressor of metastasis and invasion in gastric cancer. Clin Epigenetics [Internet]. 2017;9(1):114. https:\/\/doi.org\/10.1186\/s13148-017-0413-8","DOI":"10.1186\/s13148-017-0413-8"},{"issue":"7","key":"581_CR45","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.7150\/jca.38880","volume":"11","author":"V Borgna","year":"2020","unstructured":"Borgna V, Lobos-Gonz\u00e1lez L, Guevara F, Landerer E, Bendek M, \u00c1vila R, et al. Targeting antisense mitochondrial noncoding RNAs induces bladder cancer cell death and inhibition of tumor growth through reduction of survival and invasion factors. J Cancer. 2020;11(7):1780\u201391.","journal-title":"J Cancer"},{"key":"581_CR46","doi-asserted-by":"publisher","first-page":"173910","DOI":"10.1016\/j.ejphar.2021.173910","volume":"896","author":"L Ortega","year":"2021","unstructured":"Ortega L, Lobos-Gonz\u00e1lez L, Reyna-Jeldes M, Cerda D, De la Fuente-Ortega E, Castro P, et al. The \u03a9-3 fatty acid docosahexaenoic acid selectively induces apoptosis in tumor-derived cells and suppress tumor growth in gastric cancer. Eur J Pharmacol. 2021;896:173910.","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"581_CR47","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1002\/bit.26845","volume":"116","author":"AS Nunes","year":"2019","unstructured":"Nunes AS, Barros AS, Costa EC, Moreira AF, Correia IJ. 3D tumor spheroids as in vitro models to mimic in vivo human solid tumors resistance to therapeutic drugs. Biotechnol Bioeng. 2019;116(1):206\u201326.","journal-title":"Biotechnol Bioeng"},{"issue":"12","key":"581_CR48","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.3390\/pharmaceutics12121186","volume":"12","author":"B Pinto","year":"2020","unstructured":"Pinto B, Henriques AC, Silva PMA, Bousbaa H. Three-Dimensional spheroids as in Vitro Preclinical models for Cancer Research. Pharmaceutics. 2020;12(12):1186.","journal-title":"Pharmaceutics"},{"issue":"1","key":"581_CR49","doi-asserted-by":"publisher","first-page":"19103","DOI":"10.1038\/srep19103","volume":"6","author":"M Zanoni","year":"2016","unstructured":"Zanoni M, Piccinini F, Arienti C, Zamagni A, Santi S, Polico R, et al. 3D tumor spheroid models for in vitro therapeutic screening: a systematic approach to enhance the biological relevance of data obtained. Sci Rep. 2016;6(1):19103.","journal-title":"Sci Rep"},{"issue":"2","key":"581_CR50","doi-asserted-by":"publisher","first-page":"149","DOI":"10.3390\/organoids1020012","volume":"1","author":"Y Zhu","year":"2022","unstructured":"Zhu Y, Kang E, Wilson M, Basso T, Chen E, Yu Y, et al. 3D Tumor Spheroid and Organoid to Model Tumor Microenvironment for Cancer Immunotherapy. Organoids. 2022;1(2):149\u201367.","journal-title":"Organoids"},{"issue":"1","key":"581_CR51","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1186\/s13287-024-03880-4","volume":"15","author":"Z Abbasi-Malati","year":"2024","unstructured":"Abbasi-Malati Z, Khanicheragh P, Narmi MT, Mardi N, Khosrowshahi ND, Hiradfar A, et al. Tumoroids, a valid preclinical screening platform for monitoring cancer angiogenesis. Stem Cell Res Ther. 2024;15(1):267.","journal-title":"Stem Cell Res Ther"},{"issue":"4","key":"581_CR52","doi-asserted-by":"publisher","first-page":"883","DOI":"10.3390\/cancers12040883","volume":"12","author":"SK Singh","year":"2020","unstructured":"Singh SK, Mishra MK, Rivers BM, Gordetsky JB, Bae S, Singh R. Biological and clinical significance of the CCR5\/CCL5 Axis in Hepatocellular Carcinoma. Cancers (Basel). 2020;12(4):883.","journal-title":"Cancers (Basel)"},{"issue":"9","key":"581_CR53","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1038\/s41388-021-02174-w","volume":"41","author":"A DiNatale","year":"2022","unstructured":"DiNatale A, Kaur R, Qian C, Zhang J, Marchioli M, Ipe D, et al. Subsets of cancer cells expressing CX3CR1 are endowed with metastasis-initiating properties and resistance to chemotherapy. Oncogene. 2022;41(9):1337\u201351.","journal-title":"Oncogene"},{"issue":"12","key":"581_CR54","doi-asserted-by":"publisher","first-page":"4199","DOI":"10.3390\/ijms21124199","volume":"21","author":"M Novak","year":"2020","unstructured":"Novak M, Koprivnikar Krajnc M, Hrastar B, Breznik B, Majc B, Mlinar M, et al. CCR5-Mediated signaling is involved in Invasion of Glioblastoma Cells in its Microenvironment. Int J Mol Sci. 2020;21(12):4199.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"581_CR55","doi-asserted-by":"publisher","first-page":"20066","DOI":"10.1038\/s41598-019-56273-6","volume":"9","author":"M Azharuddin","year":"2019","unstructured":"Azharuddin M, Roberg K, Dhara AK, Jain MV, Darcy P, Hinkula J, et al. Dissecting multi drug resistance in head and neck cancer cells using multicellular tumor spheroids. Sci Rep. 2019;9(1):20066.","journal-title":"Sci Rep"},{"key":"581_CR56","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.omto.2020.05.012","volume":"18","author":"J Panneerselvam","year":"2020","unstructured":"Panneerselvam J, Mohandoss P, Patel R, Gillan H, Li M, Kumar K, et al. DCLK1 regulates Tumor Stemness and Cisplatin Resistance in Non-small Cell Lung Cancer via ABCD-Member-4. Mol Ther Oncolytics. 2020;18:24\u201336.","journal-title":"Mol Ther Oncolytics"},{"issue":"13","key":"581_CR57","doi-asserted-by":"publisher","first-page":"16948","DOI":"10.18632\/oncotarget.7659","volume":"7","author":"S Raghavan","year":"2016","unstructured":"Raghavan S, Mehta P, Horst EN, Ward MR, Rowley KR, Mehta G. Comparative analysis of tumor spheroid generation techniques for differential in vitro drug toxicity. Oncotarget. 2016;7(13):16948\u201361.","journal-title":"Oncotarget"},{"issue":"1","key":"581_CR58","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s13578-021-00548-x","volume":"11","author":"C Li","year":"2021","unstructured":"Li C, Qiu J, Xue Y. Low-dose Diosbulbin-B (DB) activates tumor-intrinsic PD-L1\/NLRP3 signaling pathway mediated pyroptotic cell death to increase cisplatin-sensitivity in gastric cancer (GC). Cell Biosci. 2021;11(1):38.","journal-title":"Cell Biosci"},{"key":"581_CR59","doi-asserted-by":"crossref","unstructured":"Greten FR, Grivennikov SI. Inflammation and Cancer: triggers, mechanisms, and consequences. Vol. 51, immunity. Cell; 2019. pp. 27\u201341.","DOI":"10.1016\/j.immuni.2019.06.025"},{"key":"581_CR60","doi-asserted-by":"crossref","unstructured":"Pabla N, Dong Z. Cisplatin nephrotoxicity: Mechanisms and renoprotective strategies. Kidney Int [Internet]. 2008;73(9):994\u20131007. https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0085253815531244","DOI":"10.1038\/sj.ki.5002786"},{"key":"581_CR61","doi-asserted-by":"publisher","unstructured":"Hrushesky PAWANDWJ. Cisplatin-associated anemia: an erythropoietin deficiency syndrome. J Clin Invest [Internet]. 1995;95(4):1650\u20139. https:\/\/doi.org\/10.1172\/JCI117840","DOI":"10.1172\/JCI117840"},{"issue":"8","key":"581_CR62","doi-asserted-by":"publisher","first-page":"e02247","DOI":"10.1016\/j.heliyon.2019.e02247","volume":"5","author":"YC Yadav","year":"2019","unstructured":"Yadav YC. Effect of cisplatin on pancreas and testes in Wistar rats: biochemical parameters and histology. Heliyon. 2019;5(8):e02247.","journal-title":"Heliyon"},{"issue":"1","key":"581_CR63","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s12885-017-3917-x","volume":"18","author":"Y Guo","year":"2018","unstructured":"Guo Y, Zeng H, Chang X, Wang C, Cui H. Additional dexamethasone in chemotherapies with carboplatin and paclitaxel could reduce the impaired glycometabolism in rat models. BMC Cancer. 2018;18(1):81.","journal-title":"BMC Cancer"},{"key":"581_CR64","doi-asserted-by":"crossref","unstructured":"Trimmer E, Essigmann JE. Cisplatin. In: Ballou DP, editor. Essays in Biochemistry Metalloproteins. Princeton University Press; 1999.","DOI":"10.1042\/bse0340191"},{"issue":"7","key":"581_CR65","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1158\/0008-5472.CAN-17-0915","volume":"78","author":"X Jiao","year":"2018","unstructured":"Jiao X, Velasco-Velazquez MA, Wang M, Li Z, Rui H, Peck AR, et al. CCR5 governs DNA damage repair and breast cancer stem cell expansion. Cancer Res. 2018;78(7):1657\u201371.","journal-title":"Cancer Res"},{"key":"581_CR66","doi-asserted-by":"crossref","unstructured":"Tupova L, Ceckova M, Ambrus C, Sorf A, Ptackova Z, Gaborik Z. Interactions between Maraviroc and the ABCB1, ABCG2, and ABCC2 transporters : an important role in Transplacental Pharmacokinetics. 2019;1(September):954\u201360.","DOI":"10.1124\/dmd.119.087684"}],"container-title":["Biological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40659-024-00581-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40659-024-00581-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40659-024-00581-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T12:38:57Z","timestamp":1737203937000},"score":1,"resource":{"primary":{"URL":"https:\/\/biolres.biomedcentral.com\/articles\/10.1186\/s40659-024-00581-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,18]]},"references-count":66,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["581"],"URL":"https:\/\/doi.org\/10.1186\/s40659-024-00581-3","relation":{},"ISSN":["0717-6287"],"issn-type":[{"value":"0717-6287","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,18]]},"assertion":[{"value":"9 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethical Committee of Universidad de La Frontera (Approval certificate N\u00ba020\/2021) and Ethical Committee of Universidad del Desarrollo (Approval certificate N\u00ba07\/2021_CICUAL-UDD).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"These results of this study are protected by a patent application filed with the Instituto Nacional de Propiedad Industrial (INAPI) under Application number PCT\/CL2024\/050006.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patents"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"There is a patent pending issued. The results of this study are protected by a patent application filed with the Instituto Nacional de Propiedad Industrial (INAPI) under Application number PCT\/CL2024\/050006.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4"}}